Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) (REPEAT)

This study has been completed.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
I.S. Nijhof, UMC Utrecht
ClinicalTrials.gov Identifier:
NCT01352338
First received: April 13, 2011
Last updated: February 25, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2016
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)